Skip to main content
Clinical Trials/NCT04656080
NCT04656080RecruitingNot Applicable

AlloSure Test Characteristics in Immunologically Quiescent and Immunologically Active Heart Transplant Recipients: Does Maximal Cardiopulmonary Stress Testing Prior to Assay Preserve Test Specificity While Enhancing Sensitivity?

Baylor Research Institute1 site in 1 country27 target enrollmentStarted: May 21, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
27
Locations
1
Primary Endpoint
• Comparison of level of cell-free DNA

Study Overview

Brief Summary

  1. Cell-free DNA does not vary significantly as a function of the activity of immunologically quiescent cardiac transplant recipients, despite the metabolic demands of the transplanted organ. (The implication of the null result would be that no restrictions to patient activity, nor modification of cardiac rehabilitation prescription, would be necessary to maintain proper test characteristics of AlloSure testing).
  2. In immunologically active cardiac transplant allografts, exercise prior to assay of donor-derived cell-free DNA can be used to increase the sensitivity of the AlloSure test. (The implication of this would be that the optimal time-frame for drawing an Allosure may actually be post-exercise, and that window will be characterized).

Detailed Description

The specific research questioned aimed to be addressed with this proposed study are:

i. Are dd-cfDNA levels in heart transplant recipients independent of recent cardiopulmonary exercise? More specifically, does the metabolic demand of maximal cardiopulmonary exercise in recent heart transplant recipients trigger a release of dd-cfDNA (if so, then what is the time course for resolution back to baseline?) ii. If dd-cfDNA does not release to any significant degree with cardiac allografts with short donor-ischemic time, does this test characteristic continue to hold for cardiac allografts transplanted after longer donor ischemic times? iii. In cardiac transplant recipients with medically stabilized, treated antibody-mediated rejection (AMR) and persistent dd-cfDNA elevation, does a discrete episode of maximal cardiometabolic activity trigger any additional elevation of dd-cfDNA, and again, with what time course?

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Post-orthotopic heart transplant patients

Exclusion Criteria

  • orthopedic, neurologic and/or any other limitations that do not allow for exercise testing on a treadmill or cycle ergometer;
  • individuals who require supplemental oxygen or have current permanent tracheostomies will be excluded from this study;
  • individuals who are discharged to a long-term acute care facility;
  • skilled nursing facility or with palliative care or hospice care will be excluded; (e) inmates and pregnant women;
  • (f) patients with antibody-mediate rejection that are not felt to be safe for cardiopulmonary stress testing.

Outcomes

Primary Outcomes

• Comparison of level of cell-free DNA

Time Frame: 10 days

Comparison of level of cell-free DNA

• Comparison of maximal oxygen consumption (VO2)

Time Frame: 10 days

• Comparison of maximal oxygen consumption (VO2)

• Cell-free DNA (AlloSure) levels after maximal cardiopulmonary exercise

Time Frame: 10 days

• Cell-free DNA (AlloSure) levels after maximal cardiopulmonary exercise

Secondary Outcomes

  • • Time-dependent changes in high-sensitivity troponin-levels(10 days)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in the Elderly - NDVaccination of elderly subjects aged 60 years and over with inactivated, split-virion inf luenza vaccine administered by the intradermal route using Vaxigrip as IM reference vaccineMedDRA version: 6.1Level: SOCClassification code 10021881
EUCTR2006-002366-18-ITSANOFI PASTEUR3,655
Active, not recruiting
Not Applicable
Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in the Elderly.Vaccination of elderly subjects aged 60 years and over with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.
EUCTR2006-002366-18-LTSanofi Pasteur SA3,655
Active, not recruiting
Not Applicable
Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in the Elderly.
EUCTR2006-002366-18-BESanofi Pasteur SA3,655
Not yet recruiting
Not Applicable
Analysis of immunological and genetic signatures in pediatric inflammatory bowel diseasesInflammatory Bowel Disease
NL-OMON48142Vrije Universiteit Medisch Centrum150
Recruiting
Not Applicable
Biomarker study using cell free DNA in patients with gastric canceradvanced gastric cancer
JPRN-UMIN000014209Kindai University Faculty of Medicine